心肌缺血预适应的研究现状及其展望  

Myocardium ischemic preconditioning:today and tomorrow

作　　者：王志农[1] 张宝仁[1] 

机构地区：[1]第二军医大学长海医院胸心外科,解放军胸心外科研究所上海200433

出　　处：《第二军医大学学报》2004年第4期352-354,共3页Academic Journal of Second Military Medical University

基　　金：上海市曙光计划资助项目 ( 0 2 SG3 0 ) ;上海市青年科技启明星计划资助项目 ( 0 0 QB14 0 5 3 )

摘　　要：缺血预适应 (ischem ic preconditioning,IPC)现象的发现 ,为心肌缺血再灌注损伤的预防开拓了一个新的研究领域。IPC是一种最为有效的内源性保护机制 ,其特点是保护作用强、保护范围广 ,对心脏保护作用包括快速相和延迟相两个时相。本文对 IPC的特点、可能的机制 ,特别是蛋白激酶 C和线粒体 ATP敏感的钾通道的作用 ,以及 IPC的药物模拟进行探讨 ,并提出药物预适应可能是今后Ischemic preconditioning (IPC), as a powerful endogenous cardioprotective adaptation, has brought a new research field for prevention and inhibition of myocardial ischemic reperfusion injury. This article is to evaluate the current information regarding the process of IPC and the possible mechanisms involved, with special attention paid to the protein kinase C and mitochondrial ATP sensitive potassium channels. The article also pointed out that the future role of IPC in clinical practice would strongly depend on the exact cellular and molecular mechanism underlying the IPC phenomenon. Pharmacological preconditioning seems to represent a perspective role of IPC in clinical practice.

关 键 词：心肌缺血 预适应 研究现状 再灌注损伤 

分 类 号：R542.2[医药卫生—心血管疾病]